MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Dopamine receptor antagonists"

  • 2024 International Congress

    Initial Results After Launch of Best Practice Advisory for Contraindicated Agents in Parkinson’s Disease and Related disorders

    N. Shah, N. Chunga, K. Amodeo, I. Richard (Rochester, USA)

    Objective: To describe factors associated with triggering a best practice advisory (BPA) for dopamine-blocking agents (DBA) and report preliminary outcomes in hospitalized persons with Parkinson’s…
  • 2024 International Congress

    Rare Clinical Manifestation of Tardive Dyskinesia In Schizophrenic Patient on Quetiapine and Sertraline: A Case Report

    H. Oktaviani, A. Tiksnadi, D. Tunjungsari (Jakarta, Indonesia)

    Objective: To underscore the rarity of tardive dyskinesia manifestation in a schizophrenic patient, prescribed second-generation DRBA agents, quetiapine and SSRI sertraline. Background: Tardive dyskinesia is…
  • 2024 International Congress

    Safety and Tolerability of Ecopipam in Tourette Syndrome (TS) with Psychiatric Comorbidities.

    D. Gilbert, S. Atkinson, G. Karkanias, R. Munschauer, S. Wanaski, T. Cunniff (Cincinnati, USA)

    Objective: Evaluate the effect of ecopipam in children and adolescents with TS on measures of attention deficit disorder (ADHD), anxiety disorders (ANX), obsessive-compulsive disorder (OCD)…
  • 2024 International Congress

    Ecopipam does not adversely affect Metabolic Parameters in Pediatric Subjects with Tourette Syndrome: Results from a Phase 2b with 12-month Open Label Extension Study

    D. Gilbert, S. Atkinson, G. Karkanias, F. Munschauer, S. Wanaski, T. Cunniff (Cincinnati, USA)

    Objective: Determine if ecopipam is associated with the emergence of clinical features suggestive of metabolic syndrome in pediatric subjects with Tourette Syndrome (TS) Background: Dopamine-2…
  • 2024 International Congress

    Antipsychotic Prescriptions Among Nursing Home Residents with Parkinson’s Disease in the End-of-Life Period

    S. Berman, A. Willis, W. Aamodt (Philadelphia, USA)

    Objective: To determine whether antipsychotic prescriptions differ between community-dwelling and nursing home residents with PD in the last 6 months of life. Background: Most antipsychotics…
  • 2024 International Congress

    Examination of how DaTscan Impacts Diagnosis in Parkinsonian Patients with and without Dopamine Receptor Blocking Agent Exposure

    R. Lopez-Castellanos, S. Factor, R. Blakes (Atlanta, USA)

    Objective: To determine whether Dopamine transporter imaging impacts diagnosis in parkinsonian patients Background: Dopamine transporter imaging (DaTscan) is a diagnostic tool used to assess loss…
  • 2024 International Congress

    Effect of Ecopipam, a Selective Dopamine-1 Receptor Antagonist, on Tic Characteristics as Assessed by the YGTSS: Results from a Phase IIb Randomized, Double-blind, Placebo-controlled Clinical Trial in Tourette Syndrome

    D. Gilbert, G. Karkanias, S. Atkinson, F. Munschauer, S. Wanaski, T. Cunniff (Cincinnati, USA)

    Objective: Assess the effect of ecopipam treatment on motor and phonic/vocal tic characteristics: number, frequency, intensity, complexity, and interference comprising the Yale Global Tic Severity…
  • 2023 International Congress

    Tardive dystonia manifesting in lid-opening apraxia, oromandibular dystonia, and laterocollis after long-term sulpiride use

    S. Brillman, T. Gongalore (Palo Alto, USA)

    Objective: We describe a patient who developed tardive dystonia after sulpiride treatment for over two decades. Few cases have been reported[1-3], thus we offer an…
  • 2023 International Congress

    Hemichorea syndrome secondary to diabetic striatopathy with contralateral drug-induced parkinsonism: a different threshold for drug induced movement disorders?

    C. Santoro, S. Landolfo, V. Velucci, G. Iliceto (Bari, Italy)

    Objective: Localized structural damages could impair the threshold of activation and/or inhibition of the nigrostriatal pathway with a mirrored effect on the healthy and pathological…
  • 2023 International Congress

    Effect of Best Practice Advisory on the administration of contraindicated medications to hospitalized patients with Parkinson’s disease and related disorders

    N. Chunga, K. Amodeo, M. Braun, B. Valdovinos, I. Richard (Rochester, USA)

    Objective: To determine if a best practice advisory (BPA) reduced the orders and administration of contraindicated dopamine blocking agents (DBA) to hospitalized patients with Parkinson’s…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley